Shots:

• The approval is based on the results from the P-IIIa STEP clinical trial program evaluating Wegovy (2.4mg injection- qw) in ~4-500 adults with obesity or overweight with at least one weight-related comorbidity
• Results: the therapy showed 17-18% average weight loss in people without T2D @68wks. and has a safe and well-tolerated profile across the program
• Wegovy is the first GLP-1 receptor agonist and is expected to launch in the US in Jun’2021. The therapy is currently under regulatory review in the EU and other countries

Ref: Globe Newswire | Image: Energy Watch